Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neurourol Urodyn ; 43(1): 88-104, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37787539

RESUMEN

OBJECTIVES: The objective of this study is to inform our hypothesis that the workplace toileting environment may impact lower urinary tract symptoms (LUTS); we examined the prevalence of LUTS across occupational groups in the Boston Area Community Health Survey. METHODS: At baseline, women (n = 3205) reported their occupation and frequency of 15 LUTS. Using the US Department of Labor's Standard Occupational Classification (SOC) system, we categorized women into 11 standard occupational groups. Prevalence ratios (PRs) were calculated by log-link generalized linear models, adjusting for age, race, education, fluid intake, and parity. Women classified in Office and Administrative Support were used as the reference group given their potential for fewer workplace toileting restrictions. RESULTS: Of the 3189 women with complete data, 68% of women reported any LUTS, ranging from 57% to 82% across the SOCs. Relative to women in Office and Administrative Support (n = 576), women in Computing, Engineering, and Science (n = 64) were more likely to report any LUTS (PR = 1.2, 95% confidence interval [95% CI]: 1.0-1.4) and urinating again in <2 h (PR = 1.7, 95% CI: 1.4-2.2), and women in Education, Legal, Community Service, Arts, and Media (n = 477), as well as Healthcare Practitioner and Technical Occupations (n = 162), were less likely to report perceived frequent daytime urination (PR = 0.6, 95% CI: 0.5-0.9 and PR = 0.6, 95% CI: 0.4-0.9, respectively). CONCLUSIONS: Our cross-sectional findings suggest that urination frequency varies across understudied occupational groups with various workplace toileting environments. Future studies should examine this relationship prospectively to inform the influence of workplace toileting environments on urination frequency, as well as the development and/or worsening of LUTS.


Asunto(s)
Síntomas del Sistema Urinario Inferior , Grupos Profesionales , Cuartos de Baño , Condiciones de Trabajo , Femenino , Humanos , Boston/epidemiología , Estudios Transversales , Síntomas del Sistema Urinario Inferior/epidemiología , Síntomas del Sistema Urinario Inferior/diagnóstico , Prevalencia , Encuestas y Cuestionarios , Condiciones de Trabajo/normas , Condiciones de Trabajo/estadística & datos numéricos , Cuartos de Baño/normas , Cuartos de Baño/estadística & datos numéricos
2.
Transl Psychiatry ; 12(1): 250, 2022 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-35705554

RESUMEN

Premenstrual dysphoric disorder (PMDD) is a female-specific condition classified in the Diagnostic and Statical Manual-5th edition under depressive disorders. Alterations in grey matter volume, cortical thickness and folding metrics have been associated with a number of mood disorders, though little is known regarding brain morphological alterations in PMDD. Here, women with PMDD and healthy controls underwent magnetic resonance imaging (MRI) during the luteal phase of the menstrual cycle. Differences in grey matter structure between the groups were investigated by use of voxel- and surface-based morphometry. Machine learning and multivariate pattern analysis were performed to test whether MRI data could distinguish women with PMDD from healthy controls. Compared to controls, women with PMDD had smaller grey matter volume in ventral posterior cortices and the cerebellum (Cohen's d = 0.45-0.76). Region-of-interest analyses further indicated smaller volume in the right amygdala and putamen of women with PMDD (Cohen's d = 0.34-0.55). Likewise, thinner cortex was observed in women with PMDD compared to controls, particularly in the left hemisphere (Cohen's d = 0.20-0.74). Classification analyses showed that women with PMDD can be distinguished from controls based on grey matter morphology, with an accuracy up to 74%. In line with the hypothesis of an impaired top-down inhibitory circuit involving limbic structures in PMDD, the present findings point to PMDD-specific grey matter anatomy in regions of corticolimbic networks. Furthermore, the results include widespread cortical and cerebellar regions, suggesting the involvement of distinct networks in PMDD pathophysiology.


Asunto(s)
Trastorno Disfórico Premenstrual , Síndrome Premenstrual , Encéfalo , Femenino , Sustancia Gris/patología , Humanos , Fase Luteínica/fisiología , Trastorno Disfórico Premenstrual/diagnóstico por imagen , Síndrome Premenstrual/patología
3.
Front Neuroendocrinol ; 59: 100869, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32822707

RESUMEN

Epidemiological, clinical, and basic research over the past thirty years have described the benefits of estrogen on cognition, mood, and brain health. Less is known about tamoxifen, a selective estrogen receptor modifier (SERM) commonly used in breast cancer which is able to cross the blood-brain barrier. In this article, we review the basic pharmacology of tamoxifenas well as its effects on cognition and mood. The literature reveals an overall impairing effect of tamoxifen on cognition in breast cancer patients, hinting at central antiestrogen activity. On the other hand, tamoxifen demonstrates promising effects in psychiatric disorders, like bipolar disorder, where its therapeutic action may be independent of interaction with estrogen receptors. Understanding the neuropsychiatric properties of SERMs like tamoxifen can guide future research to ameliorate unwanted side-effects and provide novel options for difficult to treat disorders.


Asunto(s)
Afecto/efectos de los fármacos , Antineoplásicos Hormonales/farmacología , Cognición/efectos de los fármacos , Antagonistas de Estrógenos/farmacología , Tamoxifeno/farmacología , Animales , Humanos
4.
Nat Commun ; 11(1): 1499, 2020 03 20.
Artículo en Inglés | MEDLINE | ID: mdl-32198406

RESUMEN

Extracellular vesicles (EVs) are a unique mode of intercellular communication capable of incredible specificity in transmitting signals involved in cellular function, including germ cell maturation. Spermatogenesis occurs in the testes, behind a protective barrier to ensure safeguarding of germline DNA from environmental insults. Following DNA compaction, further sperm maturation occurs in the epididymis. Here, we report reproductive tract EVs transmit information regarding stress in the paternal environment to sperm, potentially altering fetal development. Using intracytoplasmic sperm injection, we found that sperm incubated with EVs collected from stress-treated epididymal epithelial cells produced offspring with altered neurodevelopment and adult stress reactivity. Proteomic and transcriptomic assessment of these EVs showed dramatic changes in protein and miRNA content long after stress treatment had ended, supporting a lasting programmatic change in response to chronic stress. Thus, EVs as a normal process in sperm maturation, can also perform roles in intergenerational transmission of paternal environmental experience.


Asunto(s)
Vesículas Extracelulares/metabolismo , Sistema Nervioso/crecimiento & desarrollo , Proteómica , Reproducción/fisiología , Adolescente , Animales , Técnicas de Cultivo de Célula , Epidídimo/metabolismo , Epigénesis Genética , Epigenómica , Femenino , Células Germinativas , Histonas , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , MicroARNs/metabolismo , Nanopartículas , Maduración del Esperma/genética , Maduración del Esperma/fisiología , Espermatogénesis/genética , Espermatogénesis/fisiología , Espermatozoides/metabolismo , Estrés Fisiológico , Testículo
5.
Front Neuroendocrinol ; 35(3): 320-30, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24887405

RESUMEN

Sex differences are prominent in mood and anxiety disorders and may provide a window into mechanisms of onset and maintenance of affective disturbances in both men and women. With the plethora of sex differences in brain structure, function, and stress responsivity, as well as differences in exposure to reproductive hormones, social expectations and experiences, the challenge is to understand which sex differences are relevant to affective illness. This review will focus on clinical aspects of sex differences in affective disorders including the emergence of sex differences across developmental stages and the impact of reproductive events. Biological, cultural, and experiential factors that may underlie sex differences in the phenomenology of mood and anxiety disorders are discussed.


Asunto(s)
Trastornos de Ansiedad/psicología , Ansiedad/psicología , Depresión/psicología , Estrés Psicológico/psicología , Animales , Humanos , Caracteres Sexuales
6.
Arch Womens Ment Health ; 9(1): 1-14, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16206030

RESUMEN

Despite numerous studies on the topic, there is no consensus to date on the effects of oral contraceptives on mood or the mechanism(s) by which they exert these effects. This review article presents a theoretical model to explain the way in which oral contraceptives may affect mood. Specifically, it is argued that progestins exert differential effects on endogenous levels of neurosteroids, thereby altering mood. After providing an overview of the effects of estrogen, progesterone, and progesterone's metabolites on cortical excitability and the role of neurosteroids in depression and premenstrual dysphoria, this article reviews the research that has been conducted on the relationship between oral contraceptives and neurosteroids. Finally, suggestions for future research are made with the dual aim of improving existing studies on the relationship between oral contraceptives and mood and further investigating the possibility that fluctuations in neurosteroid levels are responsible for the effects of oral contraceptives on mood.


Asunto(s)
Afecto/efectos de los fármacos , Anticonceptivos Hormonales Orales/efectos adversos , Trastornos del Humor/inducido químicamente , Síndrome Premenstrual , Salud de la Mujer , Estrógenos/farmacología , Femenino , Humanos , Menstruación/efectos de los fármacos , Progesterona/farmacología , Factores de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA